Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money
An early deal with Merck was scotched for fear poor countries would be left out; now the university could make over $100 million with AstraZeneca if the technology succeeds.
Asdfgh mark this message contains misinformation
｜originally written by Asdfgh
Sarah Gilbert 沒有放棄「專利權」，目前是牛津大學擁有疫苗的獨家權利。
他們跟 AstraZeneca 的協議是：在新冠肺炎大流行期間，要以成本價出售 AZ 疫苗至少30億劑，之後繼續出售的疫苗，牛津大學則按照協議收取權利金，如果病毒流感化，這個收益可以幫助大學進行更多研究。
這是一則修改自正確訊息的謠言，後面「具有公益性質」是對的，但是「為什麼AZ最便宜，因為她放棄專利權」是錯的。
他們跟 AstraZeneca 的協議是：在新冠肺炎大流行期間，要以成本價出售 AZ 疫苗至少30億劑，之後繼續出售的疫苗，牛津大學則按照協議收取權利金，如果病毒流感化，這個收益可以幫助大學進行更多研究。
這是一則修改自正確訊息的謠言，後面「具有公益性質」是對的，但是「為什麼AZ最便宜，因為她放棄專利權」是錯的。
References
https://www.wsj.com/articles/oxford-developed-covid-vaccine-then-scholars-clashed-over-money-11603300412?fbclid=IwAR1DXmkBHLA7ybIHoAc_Wf8_ERHq_IPHACaJTj23gHYFBZhIi180r-jGGVAhttps://innovation.ox.ac.uk/technologies-available/technology-licensing/expedited-access-covid-19-related-ip/
https://healthpolicy-watch.news/ip-not-the-main-barrier-to-equitable-vaccine-rollout-say-two-leading-pharma-execs-at-who-press-conference/
https://www.ft.com/content/c474f9e1-8807-4e57-9c79-6f4af145b686
https://www.reuters.com/article/us-health-coronavirus-who-ip-idUSKBN2B0269
https://www.wsj.com/articles/oxford-developed-covid-vaccine-then-scholars-clashed-over-money-11603300412?fbclid=IwAR1DXmkBHLA7ybIHoAc_Wf8_ERHq_IPHACaJTj23gHYFBZhIi180r-jGGVA
Expedited access for COVID-19 related IP - Oxford University Innovation
The COVID-19 pandemic demands an urgent and unprecedented response. University research and expertise is critical ...
Cannot get data from URL
Subscribe to read | Financial Times
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
Waiving patents alone won't solve COVID-19 vaccine access: developers
Waiving intellectual property rights will not be enough to resolve COVID-19 vaccine access issues, the developers of the Oxford/Astrazeneca and the Pfizer/BioNTech vaccines said on Monday, ahead of a
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.